Publication: Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder
Issued Date
2012-12-01
Resource Type
ISSN
1533712X
02710749
02710749
Other identifier(s)
2-s2.0-84870253681
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Psychopharmacology. Vol.32, No.6 (2012), 814-819
Suggested Citation
Shefali Miller, Pichai Ittasakul, Po W. Wang, Shelley J. Hill, Meredith E. Childers, Natalie Rasgon, Terence A. Ketter Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder. Journal of Clinical Psychopharmacology. Vol.32, No.6 (2012), 814-819. doi:10.1097/JCP.0b013e318270dea9 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14467
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder
Other Contributor(s)
Abstract
OBJECTIVE: To assess longer-term ziprasidone effectiveness in obese and non-obese patients with bipolar disorder (BD). METHODS: Outpatients assessed with the Systematic Treatment Enhancement Program for BD Affective Disorders Evaluation and monitored with the Systematic Treatment Enhancement Program for BD Clinical Monitoring Form received open ziprasidone. RESULTS: Eighty-two patients (39 patients with BD I, 39 patients with BD II, and 4 patients with BD not otherwise specified; mean age, 41.1 years; females, 78.0%; obese, 48.8%) received ziprasidone combined with an average of 3.6 (in 74.4% at least 3) other prescription psychotropics and 1.2 prescription nonpsychotropics. Mean (median) ziprasidone final dose and duration were 134.3 (150) mg/d and 489 (199.5) days, respectively. Ziprasidone yielded in obese compared to nonobese patients less discontinuation (42.5% vs 71.4%, P = 0.01), albeit with a higher rate of addition of subsequent psychotropic medication (62.5% vs 35.7%, P = 0.03). Moreover, obese compared to nonobese patients had a higher rate of shift to final-visit euthymia (27.5% vs 0.0%, P = 0.0002), and more weight loss (-20.7 lbs vs -0.6 lbs, P = 0.001), and obese (but not nonobese) patients had significant improvements in mean Clinical Global Impression-Severity of Illness (decreased 0.6 points; P = 0.03) and Global Assessment of Functioning (increased 3.3 points, P = 0.01) scores. Weight change correlated significantly with Global Assessment of Functioning change (P = 0.047) but not with Clinical Global Impression-Severity of Illness change. Limitations are small sample size and open-label, uncontrolled, observational design. CONCLUSION: Controlled and additional observational studies seem warranted to confirm our preliminary findings suggesting ziprasidone may be more effective in obese compared to nonobese patients with BD already receiving combination pharmacotherapy. Copyright © 2012 Lippincott Williams & Wilkins.